E.H. Tan

3.1k total citations · 2 hit papers
23 papers, 2.4k citations indexed

About

E.H. Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, E.H. Tan has authored 23 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in E.H. Tan's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Head and Neck Cancer Studies (7 papers). E.H. Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Head and Neck Cancer Studies (7 papers). E.H. Tan collaborates with scholars based in Singapore, United States and China. E.H. Tan's co-authors include Kristine Pemberton, Kevin Carroll, Sumitra Thongprasert, Venice Archer, Nick Thatcher, Purvish M. Parikh, Joachim von Pawel, Alex Y. Chang, Tudor–Eliade Ciuleanu and José Rodrigues Pereira and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

E.H. Tan

18 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 1.7k citations Nick Thatcher, Alex Y. Chang et al. The Lancet profile →
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

2017 398 citations Luis Paz‐Ares, E.H. Tan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E.H. Tan Singapore	8	2.0k	1.8k	544	367	272	23	2.4k
Georgina Speake United Kingdom	11	1.8k 0.9×	1.5k 0.9×	583 1.1×	532 1.4×	176 0.6×	16	2.3k
Xiuyu Julie Cong United States	13	1.3k 0.7×	1.2k 0.7×	563 1.0×	189 0.5×	197 0.7×	19	1.7k
Eng-Huat Tan Singapore	12	901 0.5×	857 0.5×	393 0.7×	155 0.4×	242 0.9×	12	1.3k
G. Robinet France	23	2.3k 1.2×	2.1k 1.2×	522 1.0×	325 0.9×	80 0.3×	110	3.0k
Cesare Gridelli Italy	18	2.4k 1.2×	2.1k 1.2×	527 1.0×	270 0.7×	49 0.2×	37	2.9k
Jessica Menis Italy	21	1.1k 0.6×	1.2k 0.7×	381 0.7×	363 1.0×	62 0.2×	76	1.9k
J. Bérille France	16	2.3k 1.2×	2.4k 1.4×	484 0.9×	283 0.8×	44 0.2×	48	3.1k
Patrick Peterson United States	21	2.2k 1.1×	1.8k 1.0×	472 0.9×	310 0.8×	54 0.2×	55	2.6k
Purvish Parikh India	9	2.1k 1.1×	1.8k 1.0×	521 1.0×	412 1.1×	39 0.1×	21	2.6k
Mauro Zukin Brazil	13	2.8k 1.4×	2.4k 1.3×	748 1.4×	519 1.4×	43 0.2×	38	3.5k

Countries citing papers authored by E.H. Tan

Since Specialization

Citations

This map shows the geographic impact of E.H. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.H. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.H. Tan more than expected).

Fields of papers citing papers by E.H. Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.H. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.H. Tan. The network helps show where E.H. Tan may publish in the future.

Co-authorship network of co-authors of E.H. Tan

This figure shows the co-authorship network connecting the top 25 collaborators of E.H. Tan. A scholar is included among the top collaborators of E.H. Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.H. Tan. E.H. Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fan, Ziyi, E.H. Tan, & Bin Song. (2025). Precise regulation of RAS-Mediated PI3Kα activation: therapeutic potential of BBO-10203 in cancer treatment. Experimental Hematology and Oncology. 14(1). 115–115.

Passaro, Antonio, Filippo de Marinis, Hai‐Yan Tu, et al.. (2019). Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials. Annals of Oncology. 30. ix169–ix170.

Halmos, Balázs, E.H. Tan, Ross A. Soo, et al.. (2018). P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S470–S471.

Mok, Tony, Solange Peters, D. Ross Camidge, et al.. (2017). Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Annals of Oncology. 28. x191–x191. 8 indexed citations

Paz‐Ares, Luis, E.H. Tan, Kenneth J. O’Byrne, et al.. (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 28(2). 270–277. 398 indexed citations breakdown →

Schüler, Martin, Luis Paz‐Ares, Lecia V. Sequist, et al.. (2017). First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. European Journal of Cancer. 72. S176–S177. 1 indexed citations

Tan, E.H., Giuseppe Luigi Banna, Rodryg Ramlau, et al.. (2016). Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2). Annals of Oncology. 27. vi446–vi446.

Passaro, Antonio, Myung‐Ju Ahn, Balázs Halmos, et al.. (2015). Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Annals of Oncology. 26. vi77–vi77. 3 indexed citations

Jain, Amit, Si‐Lin Koo, Quan Sing Ng, et al.. (2012). Influence of Smoking Status on Response to EGFR TKI – A Retrospective Analysis of Reflex EGFR Mutation Testing in Asian Patients with Advanced Lung Adenocarcinomas. Annals of Oncology. 23. ix412–ix412.

10.

Tan, E.H., Wan‐Teck Lim, Khee Chee Soo, et al.. (2011). Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology. 23(4). 1010–1016. 18 indexed citations

11.

Wee, Joseph, E.H. Tan, Bee Choo Tai, et al.. (2006). 28. International Journal of Radiation Oncology*Biology*Physics. 66(3). S16–S16. 4 indexed citations

12.

Thatcher, Nick, Alex Y. Chang, Purvish M. Parikh, et al.. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet. 366(9496). 1527–1537. 1688 indexed citations breakdown →

13.

Tan, E.H., Anne Ann Ling Hsu, P. Eng, et al.. (2005). P-123 Molecular profiling of lung cancers: Can it be used as a clinicaltool?. Lung Cancer. 49. S147–S147. 1 indexed citations

14.

Zhou, Qiong, E.H. Tan, Ron H.J. Mathijssen, et al.. (2005). Molecular mechanisms of interethnic differences in irinotecan disposition: Impact of variants in ABCG2. Journal of Clinical Oncology. 23(16_suppl). 2018–2018. 2 indexed citations

15.

Poon, Dennis, Balram Chowbay, Swan Swan Leong, et al.. (2004). Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). Journal of Clinical Oncology. 22(14_suppl). 5576–5576. 2 indexed citations

16.

Poon, Dennis, Swan Swan Leong, YB Cheung, et al.. (2004). Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). Journal of Clinical Oncology. 22(14_suppl). 5576–5576. 1 indexed citations

17.

Zhou, Qingyu, et al.. (2004). Pharmacogenetics of the epidermal growth factor receptor (EGFR) gene in Chinese, Malay and Indian populations. Journal of Clinical Oncology. 22(14_suppl). 3019–3019. 1 indexed citations

18.

Ong, Yew Kwang, Derrick Heng, Byung Ha Chung, et al.. (2003). Design of a prognostic index score for metastatic nasopharyngeal carcinoma. European Journal of Cancer. 39(11). 1535–1541. 89 indexed citations

19.

Tan, E.H.. (2000). Vinorelbine, ifosfamide and cisplatin in non-small cell lung cancer. Lung Cancer. 29(1). 78–78. 2 indexed citations

20.

Tan, E.H., Eu Tiong Chua, Joseph Wee, et al.. (1999). Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. International Journal of Radiation Oncology*Biology*Physics. 45(3). 597–601. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact